Data from eight participants continue to support safety and tolerability profile of tegoprubartMean eGFR increased over the measurement period, ...
Q4 2025 Earnings Call January 22, 2026 10:00 AM ESTCompany ParticipantsJames Eccher - President, CEO & Chairman of ...
BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runway ...
LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA acti ...
William Dale appointed Chief Financial Officer effective January 12, 2026Simon Oxley to continue as a consultant to XCF ...
Detailed price information for Pacira Pharm Inc (PCRX-Q) from The Globe and Mail including charting and trades.
As part of the transition, Jay Wells, Executive Vice President and Chief Financial Officer, has departed the Company. During the transition period, Scott Henderson, Americold’s Chief Investment ...
The first takeaway is that our financial performance for 2024 is not indicative of our future expectations. You'll hear from ...
On Page 3 of our slides, you will see today's presenters and our bios, including President, Mike Stewart; Chief Credit ...
ELPIS II top-line trial results are anticipated in the third quarter of 2026Laromestrocel Biological License Application (BLA) submission for ...
USA News Group News Commentary ? Global defense expenditure reached an unprecedented $2.718 trillion in 2024, marking the steepest year-over-year rise since the Cold War as NATO members alone deployed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results